A 62-year-old man with HBsAg-positive cirrhosis and a 2.8 cm HCC nodule (BCLC stage A, no vascular invasion) is not a surgical candidate due to poor hepatic reserve. Which is the preferred drug of choice for locoregional therapy bridging to transplantation?

Explanation

## Locoregional Therapy for Early-Stage HCC: TACE as Bridge to Transplant **Key Point:** Transarterial chemoembolization (TACE) with doxorubicin is the preferred locoregional therapy for BCLC stage A HCC in patients awaiting liver transplantation, with the goal of controlling tumor growth and preventing dropout from the transplant list. ### BCLC Staging & Treatment Algorithm ```mermaid flowchart TD A[HCC Diagnosis]:::outcome --> B{Tumor burden & liver function?}:::decision B -->|BCLC 0-A: Single ≤2cm OR ≤3 nodules ≤3cm| C{Transplant candidate?}:::decision C -->|Yes, awaiting TX| D[TACE as bridge therapy]:::action C -->|No, good reserve| E[Resection or RFA]:::action B -->|BCLC B: Multinodular, no vascular invasion| F[TACE]:::action B -->|BCLC C: Vascular invasion or metastases| G[Systemic therapy: Atezolizumab+Bev or TKI]:::action D --> H[Maintain within transplant criteria]:::outcome E --> I[Curative intent]:::outcome F --> J[Bridging/downstaging]:::outcome G --> K[Palliative control]:::outcome ``` ### Why TACE for This Patient? | Feature | TACE | Systemic Therapy (Sorafenib/Lenvatinib) | Resection/RFA | |---------|------|------------------------------------------|---------------| | **Indication** | BCLC A–B, awaiting TX | BCLC C, advanced | Good liver reserve | | **Mechanism** | Ischemia + chemotherapy | Systemic inhibition | Curative removal | | **Transplant eligibility** | Preserves; within Milan criteria | May delay TX; systemic toxicity | Curative; no TX needed | | **Response rate** | 60–80% (complete/partial) | 30–40% | 90%+ if R0 resection | | **Hepatic reserve impact** | Minimal; locoregional | Systemic; monitor LFTs | Depends on resection extent | **Clinical Pearl:** TACE is the gold standard for bridging HCC patients to transplantation because it: 1. Controls tumor growth and prevents dropout from the transplant waiting list 2. Maintains Milan criteria (≤1 nodule ≤5 cm OR ≤3 nodules ≤3 cm) 3. Avoids systemic toxicity that might compromise transplant candidacy 4. Has high response rates (60–80%) with acceptable safety in cirrhotic patients **High-Yield:** The Milan criteria are the most widely used selection criteria for HCC transplantation. TACE is used to downstage tumors exceeding Milan criteria or to bridge patients awaiting donor availability. ### Mechanism of TACE 1. **Arterial catheterization** of the hepatic artery branch supplying the tumor 2. **Infusion of chemotherapy** (doxorubicin, cisplatin, or irinotecan) mixed with lipiodol 3. **Embolization** with particles (polyvinyl alcohol, microspheres) to occlude blood supply 4. **Result:** Ischemic necrosis + chemotherapy cytotoxicity **Mnemonic:** **TACE = Tumor Artery Chemotherapy Embolization** — remember it targets the tumor's blood supply, not the whole liver. ### Why Not Systemic Therapy Here? - **Sorafenib/Lenvatinib:** Reserved for BCLC C (advanced) disease with vascular invasion or metastases; this patient is BCLC A (early-stage) - **Systemic agents** may delay transplantation and introduce systemic toxicity in a patient with compromised hepatic function - **Atezolizumab + bevacizumab:** First-line for unresectable/advanced HCC; not indicated for early-stage, transplant-eligible patients **Warning:** Do not confuse locoregional therapy (TACE) with systemic therapy (TKIs, immunotherapy). TACE is preferred for early-stage, transplant-eligible HCC; systemic therapy is for advanced disease.